| Title |
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
|
|---|---|
| Published in |
International Journal of Nephrology and Renovascular Disease, June 2010
|
| DOI | 10.2147/ijnrd.s7038 |
| Pubmed ID | |
| Authors |
Elizabeth Ripley, Ari Hirsch |
| Abstract |
Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago. During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and pharmacodynamic characteristics and effects that are unique and are not a class effect. For example, a shorter duration of action is seen with this first ARB compared with other more recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other ARBs. This review presents the physiological effects of losartan on the kidney and discusses relevant clinical outcomes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 19% |
| Student > Bachelor | 10 | 14% |
| Student > Master | 10 | 14% |
| Other | 5 | 7% |
| Researcher | 3 | 4% |
| Other | 9 | 13% |
| Unknown | 21 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 14% |
| Agricultural and Biological Sciences | 7 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Chemistry | 3 | 4% |
| Other | 8 | 11% |
| Unknown | 23 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2021.
All research outputs
#3,181,000
of 24,079,362 outputs
Outputs from International Journal of Nephrology and Renovascular Disease
#32
of 246 outputs
Outputs of similar age
#12,026
of 99,103 outputs
Outputs of similar age from International Journal of Nephrology and Renovascular Disease
#2
of 2 outputs
Altmetric has tracked 24,079,362 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 246 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 99,103 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.